ANRO

$0.00

(

+0.00%

)
Quote details

stock

Alto Neuroscience, Inc.

NYSE | ANRO

3.95

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$102.89M

Market Cap

-

P/E Ratio

-2.39

EPS

$15.04

52 Week High

$1.60

52 Week Low

HEALTHCARE

Sector

ANRO Chart

Recent Chart
Price Action

ANRO Technicals

Tags:

ANRO Earnings

Yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -$502K
Total Revenue $0
Cost Of Revenue $502K
Costof Goods And Services Sold $502K
Operating Income -$69M
Selling General And Administrative $22M
Research And Development $47M
Operating Expenses $68M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $8.9M
Interest Expense $1.4M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$5.8M
Income Before Tax -$61M
Income Tax Expense -$61M
Interest And Debt Expense -
Net Income From Continuing Operations -$61M
Comprehensive Income Net Of Tax -
Ebit -$63M
Ebitda -$69M
Net Income -$61M

Revenue & Profitability

Earnings Performance

ANRO Financials

yearly Balance Sheet (As of Sep 30, 2024)

Field Value (USD)
Total Assets $178M
Total Current Assets $169M
Cash And Cash Equivalents At Carrying Value $168M
Cash And Short Term Investments $168M
Inventory -
Current Net Receivables -
Total Non Current Assets $8.2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.1M
Other Non Current Assets -
Total Liabilities $26M
Total Current Liabilities $10M
Current Accounts Payable $1.6M
Deferred Revenue -
Current Debt -
Short Term Debt $870K
Total Non Current Liabilities $16M
Capital Lease Obligations $5.4M
Long Term Debt $12M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $17M
Other Current Liabilities $7.6M
Other Non Current Liabilities -
Total Shareholder Equity $151M
Treasury Stock -
Retained Earnings -$138M
Common Stock $3K
Common Stock Shares Outstanding $25M

yearly Cash Flow (As of Sep 30, 2024)

Field Value (USD)
Operating Cashflow -$47M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $502K
Capital Expenditures $2.1M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$2.1M
Cashflow From Financing $136M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$61M

yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -$502K
Total Revenue $0
Cost Of Revenue $502K
Costof Goods And Services Sold $502K
Operating Income -$69M
Selling General And Administrative $22M
Research And Development $47M
Operating Expenses $68M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $8.9M
Interest Expense $1.4M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$5.8M
Income Before Tax -$61M
Income Tax Expense -$61M
Interest And Debt Expense -
Net Income From Continuing Operations -$61M
Comprehensive Income Net Of Tax -
Ebit -$63M
Ebitda -$69M
Net Income -$61M

ANRO News

ANRO Profile

Alto Neuroscience, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for psychiatric disorders. Leveraging advanced neurobiological research, the company aims to address unmet needs in mental health care. Headquartered in Los Altos, California, Alto Neuroscience is dedicated to pioneering the next generation of psychiatric treatments through its unique drug development pipelines and commitment to scientific excellence.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
BIAF
+55.13%
$5.29
RGTI
-2.86%
$31.18
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
BIAF
+55.13%
$5.29
RGTI
-2.86%
$31.18
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.